Clinical trial · Observational
Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients
Exercise Capacity, Physical Activity Level and Quality of Life in Newly Diagnosed Hematologic Malignant Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hematologic malignancies are neoplasms that affect the blood, bone marrow, and lymph nodes. Hematological malignancies are the most common forms of leukemia, lymphoma, and myeloma, with numerous subtypes. The general symptoms of leukemia are fatigue, increased susceptibility to infection, bleeding, and the formation of bruises easily. Typical lymphoma symptoms are night sweats and involuntary weight loss, recurrent fever, fatigue, and itching. Myeloma patients often have bone pain, fatigue, anemia, hypercalcemia or infection symptoms. Adverse effects of hematologic malignancies and treatments cause abnormality in physical function and quality of life. Treatments such as chemotherapy, radiotherapy and hematopoietic stem cell transplantation, which may have side effects on the body systems are used in early or late period. The most common side effect due to chemotherapy is fatigue. Vomiting, weight loss, anemia, depression, decreased aerobic capacity, loss of muscle strength, decreased physical functioning and deterioration in the quality of life are indirect side effects seen in patients. In the literature, side effects of hematological malignancies have been investigated after treatment in patients. However, no study investigated exercise capacity, quality of life, physical activity level and pulmonary functions on newly diagnosed hematologic malignant patients. Therefore, the investigators aimed to compare aforementioned outcomes in newly diagnosed hematologic malignant patients and healthy controls.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Newly diagnosed individuals
- description
- Newly diagnosed hematologic malignant patients included in the study. Inclusion and exclusion criteria were considered.
- label
- Healthy individuals
- description
- Those without chronic disease were included in the study. Inclusion and exclusion criteria were considered.
Primary outcomes (5)
- measure
- Functional exercise capacity
- timeFrame
- first day
- description
- Evaluated using 6-minute walking test
- measure
- Physical activity
- timeFrame
- first day
- description
- Evaluated using a metabolic holter
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed hematological malignant patients * 18-65 years of age * under standard medications. Exclusion Criteria: * having cognitive disorder, * orthopedic or neurological disease with a potential to affect functional capacity, * comorbidities such as asthma, chronic obstructive pulmonary disease (COPD), acute infections or pneumonia, * problems which may prevent evaluating such as visual problems and mucositis * having metastasis to any region (bone etc.) * having acute hemorrhage in the intracranial and / or lung and other areas * having any contraindication to exercise training
References
Publications (0)
Data not yet available